



Prana Biotechnology Added to Forbes Neurological Drug Watch List

MELBOURNE, Australia, March 26 /PRNewswire-FirstCall/ -- Prana Biotechnology Limited (NASDAQ-SMALL:PRAN) (ASX: PBT; Nasdaq: PRAN) today announced that Forbes.com has added Prana to its list of "neurological drugs to watch," highlighting the most promising experimental drugs to treat diseases of the brain and nervous system.

Harvard University's Professor Ashley Bush, M.D., Ph.D., is described as a "provocative scientist", whose approach to treating Alzheimer's Disease is distinct from that of most big drug companies. Dr. Bush argues that copper and zinc interact with proteins in the brain (beta-amyloid) to make them toxic.

Professor Bush has recently entered into a 10-year extension consultancy agreement with Prana.

To obtain the article of Forbes 'Neurological Drugs to Watch', please go to: http://www.forbes.com/2004/01/26/cx_mh_rl_neurotearsheet_print.html

About Prana:

Prana is a Melbourne-based biotechnology company established in 1997 to commercialize research into Alzheimer's disease and other major age-related degenerative disorders (ASX: PBT; Nasdaq: PRAN). Prana's technology was discovered by the company's researchers at prominent international institutions including Massachusetts General Hospital at Harvard Medical School, the University of Melbourne and the Mental Health Research Institute in Melbourne.

###

Contacts:

Media – Australia	Media – New York	Company
Kate Mazoudier Buchan Phone: +61 3 9866 4722 / 0403 497 424 kmazoudier@bcg.com.au	Ivette Almeida or Steven Silver Anne McBride Group Phone: + 1 212 983 1702 Silver@AnneMcBride.com	Mr Geoffrey Kempler, Executive Chairman, Prana Phone: +61 3 9690 7892 gkempler@pranabio.com